AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.

AbbVie (ABBV) announced the global Phase 3 Vevrona trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome did not meet the ...

Personalized drug treatments have outperformed chemotherapy for leukemia patients in a trial led by Leeds researchers. Newly ...

Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.

Aptose Biosciences has been thrown a financial lifeline by its own CEO while the leukemia-focused biotech scrambles around ...

A chemotherapy-free approach for some patients suffering from leukaemia could lead to better outcomes, scientists behind a ...

Pharma majors AbbVie and Roche were both trading lower early Tuesday after top-line results were announced from the global ...

Genentech, a member of the Roche Group (RHHBY), and AbbVie announced that The Phase III VERONA study, which evaluated Venclexta or venetoclax in combination with azacitidine for patients with ...

FREMONT, CA, UNITED STATES, June 16, 2025 /EINPresswire.com/ -- NEXCOM, a leading global supplier of embedded systems, announced today the launch of the EBC 370/EBC 370X, providing Edge AI computing ...

Rising elderly population, demand for personalized in-home care, and advancements in digital health to drive strong global home care market growth. NEWARK, DE, UNITED STATES, June 17, 2025 ...